| Literature DB >> 35879661 |
Jieping Yang1, Xukeng Guo1, Zonggui Zheng2, Weiqi Ke3.
Abstract
BACKGROUND: Data providing a relationship between the anesthetic method and postoperative length of stay (PLOS) is limited. We aimed to investigate whether general anesthesia alone or combined with epidural anesthesia might affect perioperative risk factors and PLOS for patients undergoing radical resection of malignant esophageal tumors.Entities:
Keywords: Epidural anesthesia; Esophageal cancer; General anesthesia; Postoperative length of stay
Mesh:
Substances:
Year: 2022 PMID: 35879661 PMCID: PMC9310395 DOI: 10.1186/s12871-022-01775-6
Source DB: PubMed Journal: BMC Anesthesiol ISSN: 1471-2253 Impact factor: 2.376
Univariate and multivariate analyses of factors associated with PLOS (days)
| Univariate | Multivariate | |||
|---|---|---|---|---|
| β (95% CI) | β (95% CI) | |||
| Age (years) | 0.11 (-0.04, 0.26) | 0.1446 | ||
| Male | -0.36 (-3.19, 2.46) | 0.8016 | ||
| History of smoking | -2.55 (-4.97, -0.13) | 0.0399 | -1.77 (-3.58, 0.04) | 0.0561 |
| Preoperative chemotherapy | -1.10 (-3.81, 1.61) | 0.4280 | ||
| Coexisting disease | ||||
| Hypertension | 1.14 (-1.98, 4.26) | 0.4754 | ||
| DM | 0.68 (-3.54, 4.90) | 0.7519 | ||
| Heart disease | -0.55 (-3.99, 2.90) | 0.7563 | ||
| Lung disease | 1.89 (-0.91, 4.69) | 0.1877 | ||
| Laboratory examination results | ||||
| PLT (109/L) | 0.00 (-0.01, 0.02) | 0.6467 | ||
| Albumin (g/L) | 0.09 (-0.20, 0.37) | 0.5481 | ||
| Scr (µmol/L) | -0.01 (-0.07, 0.05) | 0.6390 | ||
| AST (mmol/L) | -0.03 (-0.15, 0.08 | 0.2870 | ||
| ALT (mmol/L) | -0.04 (-0.12, 0.04) | 0.2870 | ||
| Preoperative anemia | -1.72 (-4.23, 0.79) | 0.1799 | ||
| Intraoperative variables | ||||
| ASA | ||||
| I/II | Reference | |||
| III | -1.17 (-5.06, 2.72)) | 0.5563 | ||
| Anesthesia type | ||||
| GA | Reference | Reference | ||
| E-GA | 1.31 (-1.12, 3.73) | 0.2920 | 0.76 (-1.01, 2.53) | 0.4016 |
| Endotracheal tube type | ||||
| Single lumen | Reference | |||
| Double lumen | 0.83 (-1.68, 3.35) | 0.5155 | ||
| Continuous anesthesia | ||||
| TIVA | Reference | |||
| CIIA | -1.02 (-4.91, 2.87) | 0.6080 | ||
| Operation type | ||||
| OE | Reference | |||
| MIE | -0.27 (-2.98, 2.45 | 0.8470 | ||
| Blood loss (ml) | 0.00 (-0.01, 0.01) | 0.5595 | ||
| Operation time (min) | 0.02 (-0.01, 0.04) | 0.1809 | ||
| Vasoactive drug use | -0.48 (-2.96, 1.99) | 0.7035 | ||
| Blood transfusion | 1.02 (-1.99, 4.03) | 0.5067 | ||
| Postoperative ICU admission | 6.31 (1.90, 10.72) | 0.0054 | 2.99 (-1.83, 7.80) | 0.2251 |
| Postoperative complications | ||||
| Respiratory failure | 5.24 (-0.24, 10.73) | 0.0621 | -0.76 (-6.61, 5.09) | 0.7983 |
| Lung infection | 4.88 (2.35, 7.41) | 0.0002 | 3.53 (1.54, 5.52) | 0.0006 |
| Anastomotic leakage | 26.62 (22.87, 30.37) | < 0.0001 | 25.73 (22.11, 29.34) | < 0.0001 |
| Surgical site infection | 7.86 (0.71, 15.02) | 0.0322 | 9.39 (4.10, 14.68) | 0.0006 |
Abbreviations: CI confidence interval, GA general anesthesia, E-GA combined epidural-general anesthesia, DM diabetes mellitus, PLT platelet, AST aspartate transaminase, ALT alanine transaminase, Scr serum creatinine, ASA American Society of Anesthesiologist Physical Status, TIVA total intravenous anesthesia, CIIA combined intravenous and inhalation anesthesia, OE open esophagectomy, MIE minimally invasive esophagectomy, ICU intensive care unit, PLOS postoperative length of stay
Relationship between the anesthesia type and prolonged PLOS (days)
| Outcome | Prolonged PLOS (days) OR (95% CI) | ||
|---|---|---|---|
| GA | Reference | Reference | Reference |
| E-GA | 1.54 (0.86, 2.74) 0.1456 | 1.54 (0.86, 2.78) 0.1473 | 1.60 (0.80, 3.23) 0.1841 |
Abbreviations: PLOS postoperative length of stay, OR odds ratio, CI confidence interval, GA general anesthesia, E-GA combined epidural-general anesthesia
Model I adjusted for age and sex
Model II adjusted for history of smoking, postoperative ICU admission, respiratory failure, lung infection, surgical site infection, and anastomotic leakage
Comparison of variables in the GA and EGA groups before and after propensity score matching
| Variable | Total | Before matching | After matching | |||||
|---|---|---|---|---|---|---|---|---|
| GA group | E-GA group | GA group | E-GA group | Standardized diff. | ||||
| N | 647 | 185 | 462 | 137 | 137 | |||
| Age (years) | 61.06 ± 8.16 | 62.44 ± 8.14 | 60.51 ± 8.11 | 0.006 | 61.89 ± 8.24 | 61.93 ± 7.77 | 0.964 | 0.0055 |
| Male | 501 (77.43%) | 140 (75.68%) | 361 (78.14%) | 0.498 | 106 (77.37%) | 101 (73.72%) | 0.482 | 0.0850 |
| History of smoking | 342 (52.86%) | 98 (52.97%) | 244 (52.81%) | 0.971 | 73 (53.28%) | 76 (55.47%) | 0.716 | 0.0440 |
| Preoperative chemotherapy | 142 (21.95%) | 55 (29.73%) | 87 (18.83%) | 0.002 | 38 (27.74%) | 38 (27.74%) | 1.000 | 0.0000 |
| Coexisting disease | ||||||||
| Hypertension | 102 (15.77%) | 41 (22.16%) | 61 (13.20%) | 0.005 | 25 (18.25%) | 26 (18.98%) | 1.0000 | 0.0188 |
| DM | 47 (7.26%) | 16 (8.65%) | 31 (6.71%) | 0.391 | 11 (8.03%) | 14 (10.22%) | 0.6748 | 0.0761 |
| Heart disease | 67 (10.36%) | 28 (15.14%) | 39 (8.44%) | 0.012 | 20 (14.60%) | 20 (14.60%) | 1.000 | 0.0000 |
| Lung disease | 150 (23.18%) | 45 (24.32%) | 105 (22.73%) | 0.664 | 33 (24.09%) | 35 (25.55%) | 0.780 | 0.0338 |
| Laboratory examination results | ||||||||
| Preoperative anemia | 237 (36.63%) | 72 (38.92%) | 165 (35.71%) | 0.445 | 51 (37.23%) | 50 (36.50%) | 0.900 | 0.0151 |
| PLT (109/L) | 233.61 ± 76.60 | 228.64 ± 72.96 | 235.60 ± 78.00 | 0.297 | 232.38 ± 77.52 | 229.96 ± 76.89 | 0.795 | 0.0314 |
| Albumin (g/L) | 39.63 ± 4.24 | 39.11 ± 5.11 | 39.84 ± 3.82 | 0.049 | 39.02 ± 4.97 | 39.38 ± 3.57 | 0.493 | 0.0830 |
| Scr (µmol/L) | 90.51 ± 23.12 | 94.69 ± 26.21 | 88.84 ± 21.57 | 0.004 | 92.62 ± 15.7) | 94.53 ± 23.96 | 0.435 | 0.0945 |
| AST (mmol/L) | 23.53 ± 10.93 | 24.49 ± 10.28 | 23.15 ± 11.17 | 0.161 | 24.63 ± 10.55 | 23.77 ± 10.80 | 0.506 | 0.0805 |
| ALT (mmol/L) | 17.00 (13.00–24.00) | 17.00 (12.02-25.00) | 17.00 (13.00–24.00) | 0.731 | 17.00 (12.02-26.00) | 17.00 (14.00–24.00) | 0.920 | 0.0732 |
| Intraoperative variables | ||||||||
| ASA | 0.005 | 0.1756 | 0.1878 | |||||
| I/II | 594 (91.81%) | 161 (87.03%) | 433 (93.72%) | 118 (86.13%) | 126 (91.97%) | |||
| III | 53 (8.19%) | 24 (12.97%) | 29 (6.28%) | 19 (13.87%) | 11 (8.03%) | |||
| Endotracheal tube type | < 0.001 | 0.803 | 0.0302 | |||||
| Single lumen | 254 (39.26%) | 133 (71.89%) | 121 (26.19%) | 87 (63.50%) | 85 (62.04%) | |||
| Double lumen | 393 (60.74%) | 52 (28.11%) | 341 (73.81%) | 50 (36.50%) | 52 (37.96%) | |||
| Continuous anesthesia | < 0.001 | 1.000 | 0.0000 | |||||
| TIVA | 587 (90.73%) | 148 (80.00%) | 439 (95.02%) | 122 (89.05%) | 122 (89.05%) | |||
| CIIA | 60 (9.27%) | 37 (20.00%) | 23 (4.98%) | 15 (10.95%) | 15 (10.95%) | |||
| Operation type | < 0.001 | 0.787 | 0.0326 | |||||
| OE | 347 (53.63%) | 40 (21.62%) | 307 (66.45%) | 39 (28.47%) | 37 (27.01%) | |||
| MIE | 300 (46.37%) | 145 (78.38%) | 155 (33.55%) | 98 (71.53%) | 100 (72.99%) | |||
| Blood loss (ml) | 200.00 (100.00-250.00) | 100.00 (100.00-200.00) | 200.00 (100.00-250.00) | 0.004 | 100.00 (100.00-200.00) | 100.00 (100.00-200.00) | 0.746 | 0.0565 |
| Operation time (min) | 239.13 ± 56.72 | 259.61 ± 55.09 | 230.93 ± 55.32 | < 0.001 | 256.43 ± 50.17 | 249.82 ± 46.57 | 0.260 | 0.1365 |
| Vasoactive drug use | 341 (52.70%) | 109 (58.92%) | 232 (50.22%) | 0.045 | 82 (59.85%) | 81 (59.12%) | 0.902 | 0.0149 |
| Blood transfusion | 127 (19.63%) | 42 (22.70%) | 85 (18.40%) | 0.213 | 26 (18.98%) | 30 (21.90%) | 0.549 | 0.0725 |
| Postoperative ICU admission | 42 (6.49%) | 18 (9.73%) | 24 (5.19%) | 0.034 | 10 (7.30%) | 12 (8.76%) | 0.657 | 0.0537 |
| Postoperative complications | ||||||||
| Respiratory failure | 24 (3.71%) | 9 (4.86%) | 15 (3.25%) | 0.325 | 6 (4.38%) | 8 (5.84%) | 0.583 | 0.0663 |
| Lung infection | 212 (32.77%) | 58 (31.35%) | 154 (33.33%) | 0.627 | 41 (29.93%) | 48 (35.04%) | 0.367 | 0.1093 |
| Anastomotic leakage | 42 (6.49%) | 11 (5.95%) | 31 (6.71%) | 0.722 | 8 (5.84%) | 10 (7.30%) | 0.626 | 0.0590 |
| Surgical site infection | 37 (5.72%) | 5 (2.70%) | 32 (6.93%) | 0.037 | 4 (2.92%) | 4 (2.92%) | 1.000 | 0.0000 |
| PLOS (days) | 19.85 ± 12.60 16.00 (14.00–21.00) | 20.01 ± 14.90 15.00 (14.00–20.00) | 19.79 ± 11.57 16.00 (14.00–21.00) | 0.094 | 18.09 ± 9.71 15.00 (14.00–18.00) | 19.39 ± 10.75 16.00 (14.00–22.00) | 0.145 | 0.1276 |
Data are expressed as the mean ± SD, median (Q1-Q3), or N (%)
Abbreviations: GA general anesthesia, E-GA combined epidural-general anesthesia, DM diabetes mellitus, PLT platelet, AST aspartate transaminase, ALT alanine transaminase, Scr serum creatinine, ASA American Society of Anesthesiologist Physical Status, TIVA total intravenous anesthesia, CIIA combined intravenous and inhalation anesthesia, OE open esophagectomy, MIE minimally invasive esophagectomy, ICU intensive care unit, PLOS postoperative length of stay
Effect size of anesthesia type on PLOS (days) in prespecified and exploratory subgroups
| Anesthesia type |
| ||
|---|---|---|---|
|
|
|
| |
| Age (years) | 0.0897 | ||
| ≤60 | 116 | -1.04 (-4.65, 2.57) | |
| >60 | 158 | 3.17 (-0.07, 6.41) | |
| Sex | 0.5597 | ||
| Female | 67 | 0.03 (-3.53, 3.59) | |
| Male | 207 | 1.70 (-1.30, 4.71) | |
| History of smoking | 0.7850 | ||
| No | 125 | 1.00 (-3.18, 5.18) | |
| Yes | 149 | 1.67 (-1.06, 4.39) | |
| Preoperative chemotherapy | 0.8566 | ||
| No | 198 | 1.44 (-1.68, 4.57) | |
| Yes | 76 | 0.95 (-2.25, 4.14) | |
| Hypertension | 0.3587 | ||
| No | 223 | 0.76 (-2.03, 3.55) | |
| Yes | 51 | 3.66 (-0.96, 8.28) | |
| DM | 0.8682 | ||
| No | 249 | 1.36 (-1.25, 3.97) | |
| Yes | 25 | 0.64 (-5.32, 6.61) | |
| Heart disease | 0.0965 | ||
| No | 234 | 0.46 (-2.27, 3.19) | |
| Yes | 40 | 6.25 (1.82, 10.68) | |
| Lung disease | 0.5707 | ||
| No | 206 | 0.88 (-1.71, 3.47) | |
| Yes | 68 | 2.49 (-3.37, 8.35) | |
| PLT (109/L) | / | ||
| < 100 | 3 | / | |
| ≥100 | 271 | 1.40 (-1.04, 3.85) | |
| Hypoproteinemia | / | ||
| No | 270 | 1.42 (-1.04, 3.88) | |
| Yes | 4 | / | |
| Scr (µmol/L) group | / | ||
| ≤ 133 | 268 | 1.35 (-1.12, 3.83) | |
| > 133 | 6 | / | |
| AST (mmol/L)group | 0.5435 | ||
| ≤ 40 | 255 | 1.34 (-1.24, 3.92) | |
| > 40 | 19 | 1.09 (-3.65, 5.83) | |
| ALT (mmol/L) group | 0.5750 | ||
| ≤ 40 | 248 | 1.06 (-1.58, 3.71) | |
| > 40 | 26 | 3.62 (-0.13, 7.36) | |
| Preoperative anemia | 0.4957 | ||
| No | 173 | 0.65 (-2.87, 4.18) | |
| Yes | 101 | 2.39 (-0.22, 4.99) | |
| ASA | / | ||
| I | 13 | 6.77 (-3.79, 17.34) | |
| II | 231 | 0.76 (-2.03, 3.54) | |
| III | 30 | 2.77 (-1.01, 6.55) | |
| Endotracheal tube type | 0.0680 | ||
| Single lumen | 172 | -0.43 (-3.19, 2.33) | |
| Double lumen | 102 | 4.21 (-0.33, 8.75) | |
| Continuous anesthesia | 0.5115 | ||
| TIVA | 244 | 1.59 (-1.08, 4.26) | |
| CIIA | 30 | -1.00 (-5.38, 3.38) | |
| Operation type | 0.0346 | ||
| OE | 76 | 5.50 (1.06, 9.94) | |
| MIE | 198 | -0.30 (-3.17, 2.58) | |
| Blood loss (ml) | / | ||
| ≤ 400 | 267 | 1.28 (-1.21, 3.77) | |
| >400 | 7 | / | |
| Operation time (min) | 0.5442 | ||
| ≤ 280 | 212 | 1.81 (-0.37, 3.98) | |
| > 280 | 62 | 0.02 (-7.77, 7.82) | |
| Vasoactive drug use | 0.0002 | ||
| No | 111 | 6.72 (2.64, 10.80) | |
| Yes | 163 | -2.39 (-5.25, 0.48) | |
| Blood transfusion | 0.0346 | ||
| No | 218 | 1.08 (-1.81, 3.98) | |
| Yes | 56 | 2.04 (-1.70, 5.78) | |
| Postoperative ICU admission | 0.5396 | ||
| No | 252 | 1.00 (-1.38, 3.37 | |
| Yes | 22 | 3.75 (-8.90, 16.40) | |
| Respiratory failure | / | ||
| No | 260 | 1.49 (-0.97, 3.95) | |
| Yes | 14 | -3.71 (-16.45, 9.03) | |
| Lung infection | 0.7764 | ||
| No | 185 | 0.82 (-0.88, 2.53) | |
| Yes | 89 | 1.55 (-4.88, 7.99) | |
| Anastomotic leakage | / | ||
| No | 256 | 1.12 (-0.19, 2.44) | |
| Yes | 18 | -2.05 (-24.46, 20.36) | |
| Surgical site infection | / | ||
| No | 266 | 1.38 (-1.07, 3.84) | |
| Yes | 8 | / | |
The following variables were excluded because ≥ 5 categories or < 20 observations in a category: PLT (109/L), AST (mmol/L), Scr (µmol/L), hypoproteinemia, ASA, blood loss (ml), respiratory failure, anastomotic leakage, and surgical site infection
Abbreviations: PLOS postoperative length of stay, CI confidence interval, DM diabetes mellitus, PLT platelet, AST aspartate transaminase, ALT alanine transaminase, Scr serum creatinine, ASA American Society of Anesthesiologist Physical Status, TIVA total intravenous anesthesia, CIIA combined intravenous and inhalation anesthesia, ICU intensive care unit; hypoproteinemia, albumin < 30 (g/L); preoperative anemia, hemoglobin < 130 g/L in males or hemoglobin < 120 g/L in females, OE open esophagectomy, MIE minimally invasive esophagectomy